Osteoneurogen (ONG) is based on a deep understanding of the mechanisms behind fibrosis on a global scale.
Further, ONG was founded primary to discover, clinical develop, co-research, license in & out, produce, and commercialize
new drug pipelines that are innovative than the existing drugs that target fibrosis, considered one of the highest medically
unmet need. We have a vision that grow into a world class bio company developing fibrosis drugs through
continuous innovation & development efforts.
ONG21001 in Preclinical
ONG21001 is currently challenging the treatment of
idiopathic pulmonary fibrosis (IPF), a rare disease which
does not have a pertinent drug currently. ONG21001,
currently under preclinical, has shown better therapeutic
efficacy than already marketed drugs in animal model and is
being tested for its potential as a next-generation drug.
ONG41008 in Discovery
NASH is a form of NAFLD that causes fibrosis due to liver
inflammation and cell damage and it may lead to cirrhosis
that could lead to loss of life. As there are no approved drugs,
many global big pharmas are on their way to developing the
drugs, and ONG41008 has shown a potential for a new drug
by significantly reducing the NAFLD scores in animal model.
Contact Our Company
We are taking historical steps to give hope to the patients
around the world through overcoming fibrosis.